Update on lupus nephritis

Clinical Journal of the American Society of Nephrology

Volumn 12, Issue 5, 2017, Pages 825-835

  Almaani, Salem ^a   Meara, Alexa ^a   Rovin, Brad H ^a  

^a THE OHIO STATE UNIVERSITY WEXNER MEDICAL CENTER   (United States)

Author keywords

Chronic; Discoid; Epidemiology and outcomes; Glomerular disease; Glomerulonephritis; Humans; Immunosuppression; Kidney; Kidney failure; Lupus Erythematosus; Lupus nephritis; Nephritis; Renal Insufficiency; Risk factors; Systemic; Systemic lupus erythematosus

Indexed keywords

CREATININE; CYCLOPHOSPHAMIDE; CYTOTOXIC T LYMPHOCYTE ANTIGEN 4; ECULIZUMAB; HLA ANTIGEN; PLATELET DERIVED GROWTH FACTOR; PROGRAMMED DEATH 1 LIGAND 1; RIBONUCLEOPROTEIN ANTIBODY; RO ANTIBODY; SM ANTIBODY; TUMOR NECROSIS FACTOR;

APOL1 GENE; APOPTOSIS; ARTICLE; CLINICAL TRIAL (TOPIC); END STAGE RENAL DISEASE; ESTIMATED GLOMERULAR FILTRATION RATE; ETHNICITY; GENE; GENETIC RISK; GENOME-WIDE ASSOCIATION STUDY; HUMAN; KAT2B GENE; KIDNEY BIOPSY; KIDNEY FUNCTION; LUPUS ERYTHEMATOSUS NEPHRITIS; META ANALYSIS (TOPIC); PATHOGENESIS; RANDOMIZED CONTROLLED TRIAL (TOPIC); SLC5A11 GENE; SOCIOECONOMICS; TREATMENT RESPONSE; BIOPSY; CHRONIC KIDNEY FAILURE; DISEASE EXACERBATION; GENETIC PREDISPOSITION; GENETICS; KIDNEY; PATHOLOGY; PATHOPHYSIOLOGY; PHENOTYPE; PREDICTIVE VALUE; PROGNOSIS; RISK FACTOR;

BIOPSY; DISEASE PROGRESSION; GENETIC PREDISPOSITION TO DISEASE; HUMANS; KIDNEY; KIDNEY FAILURE, CHRONIC; LUPUS NEPHRITIS; PHENOTYPE; PREDICTIVE VALUE OF TESTS; PROGNOSIS; RISK FACTORS;

EID: 85021709813     PISSN: 15559041     EISSN: 1555905X     Source Type: Journal    
DOI: 10.2215/CJN.05780616     Document Type: Article

References (99)

1. Schwartzman-Morris J, Putterman C: Gender differences in the pathogenesis and outcome of lupus and of lupus nephritis. Clin Dev Immunol 2012: 604892, 2012
2. Danchenko N, Satia JA, Anthony MS: Epidemiology of systemic lupus erythematosus: a comparison of worldwide disease burden. Lupus 15: 308-318, 2006
3. Mina R, Brunner HI: Pediatric lupus-are there differences in presentation, genetics, response to therapy, and damage accrual compared with adult lupus? Rheum Dis Clin North Am 36: 53-80, 7-8, 2010
4. Osio-Salido E, Manapat-Reyes H: Epidemiology of systemic lupus erythematosus in Asia. Lupus 19: 1365-1373, 2010
5. Symmons DPM: Frequency of lupus in people of African origin. Lupus 4: 176-178, 1995
6. Tiffin N, Hodkinson B, Okpechi I: Lupus in Africa: can we dispel the myths and face the challenges? Lupus 23: 102-111, 2014
7. Pons-Estel GJ, Alarcón GS, Scofield L, Reinlib L, Cooper GS: Understanding the epidemiology and progression of systemic lupus erythematosus. Semin Arthritis Rheum 39: 257-268, 2010
8. Bastian HM, Roseman JM, McGwin G Jr, Alarcón GS, Friedman AW, Fessler BJ, Baethge BA, Reveille JD; LUMINA Study Group. LUpus in MInority populations: NAture vs nurture: Systemic lupus erythematosus in three ethnic groups. XII. Risk factors for lupus nephritis after diagnosis. Lupus 11: 152-160, 2002
9. Hanly JG, O’Keeffe AG, Su L, Urowitz MB, Romero-Diaz J, Gordon C, Bae S-C, Bernatsky S, Clarke AE, Wallace DJ, Merrill JT, Isenberg DA, Rahman A, Ginzler EM, Fortin P, Gladman DD, Sanchez-Guerrero J, Petri M, Bruce IN, Dooley MA, Ramsey-Goldman R, Aranow C, Alarcón GS, Fessler BJ, Steinsson K, Nived O, Sturfelt GK, Manzi S, Khamashta MA, van Vollenhoven RF, Zoma AA, Ramos-Casals M, Ruiz-Irastorza G, Lim SS, Stoll T, Inanc M, Kalunian KC, Kamen DL, Maddison P, Peschken CA, Jacobsen S, Askanase A, Theriault C, Thompson K, Farewell V: The frequency and outcome of lupus nephritis: results from an international inception cohort study. Rheumatology (Oxford) 55: 252-262, 2016
10. Contreras G, Lenz O, Pardo V, Borja E, Cely C, Iqbal K, Nahar N, de La Cuesta C, Hurtado A, Fornoni A, Beltran-Garcia L, Asif A, Young L, Diego J, Zachariah M, Smith-Norwood B: Outcomes in AfricanAmericans andHispanicswith lupus nephritis. Kidney Int 69: 1846-1851, 2006
11. O’Shaughnessy MM, Montez-Rath ME, Lafayette RA, Winkelmayer WC: Patient characteristics and outcomes by GN subtype in ESRD. Clin J Am Soc Nephrol 10: 1170-1178, 2015
12. Hopkinson ND, Jenkinson C, Muir KR, Doherty M, Powell RJ: Racial group: Racial group, socioeconomic status, and the development of persistent proteinuria in systemic lupus erythematosus. Ann Rheum Dis 59: 116-119, 2000
13. Huong DL, Papo T, Beaufils H, Wechsler B, Blétry O, Baumelou A, Godeau P, Piette J-C: Renal involvement in systemic lupus erythematosus. A study of 180 patients from a single center. Medicine (Baltimore) 78: 148-166, 1999
14. Pons-Estel GJ, Catoggio LJ, Cardiel MH, Bonfa E, Caeiro F, Sato E, Massardo L, Molina-Restrepo JF, Toledano MG, Barile-Fabris LA, Amigo MC, Acevedo-Vásquez EM, Abadi I, Wojdyla D, Alarcón-Riquelme ME, Alarcón GS, Pons-Estel BA; GLADEL: Lupus in Latin-American patients: lessons fromtheGLADEL cohort. Lupus 24: 536-545, 2015
15. Feldman CH, Hiraki LT, Liu J, Fischer MA, Solomon DH, Alarcón GS, Winkelmayer WC, Costenbader KH: Epidemiology and sociodemographics of systemic lupus erythematosus and lupus nephritis among US adults with Medicaid coverage, 2000-2004. Arthritis Rheum 65: 753-763, 2013
16. Burgos PI, McGwin G, Pons-Estel GJ, Reveille JD, Alarcón GS, Vilá LM: US patients of Hispanic and African ancestry develop lupus nephritis early in the disease course:Data from LUMINA, a multiethnic US cohort (LUMINA LXXIV). Ann Rheum Dis 70: 393-394, 2011
17. Nee R, Martinez-Osorio J, Yuan CM, Little DJ, Watson MA, Agodoa L, Abbott KC: Survival Disparity of African American Versus Non-African American Patients With ESRD Due to SLE. Am J Kidney Dis 66: 630-637, 2015
18. Austin HA 3rd, Boumpas DT, Vaughan EM, Balow JE: High-risk features of lupus nephritis: importance of race and clinical and histological factors in 166 patients. Nephrol Dial Transplant 10: 1620-1628, 1995
19. Reveille JD, Moulds JM, Ahn C, Friedman AW, Baethge B, Roseman J, Straaton KV, Alarcón GS: Systemic lupus erythematosus in three ethnic groups: I. The effects ofHLA class II, C4, and CR1 alleles, socioeconomic factors, and ethnicity at disease onset. LUMINA StudyGroup. Lupus in minority populations, nature versus nurture. Arthritis Rheum 41: 1161-1172, 1998
20. Salmon JE, Millard S, Schachter LA, Arnett FC, Ginzler EM, Gourley MF, Ramsey-Goldman R, Peterson MG, Kimberly RP: Fc gamma RIIA alleles are heritable risk factors for lupus nephritis in African Americans. J Clin Invest 97: 1348-1354, 1996
21. Korbet SM, Schwartz MM, Evans J, Lewis EJ; Collaborative Study Group: Severe lupus nephritis: racial differences in presentation and outcome. J Am Soc Nephrol 18: 244-254, 2007
22. Lin CP, Adrianto I, Lessard CJ, Kelly JA, Kaufman KM, Guthridge JM, Freedman BI, Anaya JM, Alarcón-Riquelme ME, Pons-Estel BA, Martin J, Glenn S, Adler A, Bae SC, Park SY, Bang SY, Song YW, Boackle SA, Brown EE, Edberg JC, Alarcón GS, Petri MA, Criswell LA, Ramsey-Goldman R, Reveille JD, Vila LM, Gilkeson GS, Kamen DL, Ziegler J, Jacob CO, Rasmussen A, James JA, Kimberly RP, Merrill JT, Niewold TB, Scofield RH, Stevens AM, Tsao BP, Vyse TJ, Langefeld CD, Moser KL, Harley JB, Gaffney PM, Montgomery CG; BIOLUPUS and GENLES Networks: Role of MYH9 and APOL1 in African and non-African populations with lupus nephritis. Genes Immun 13: 232-238, 2012
23. Freedman BI, Langefeld CD, Andringa KK, Croker JA, Williams AH, Garner NE, Birmingham DJ, Hebert LA, Hicks PJ, Segal MS, Edberg JC, Brown EE, Alarcón GS, Costenbader KH, Comeau ME, Criswell LA, Harley JB, James JA, Kamen DL, Lim SS, Merrill JT, Sivils KL, Niewold TB, Patel NM, Petri M, Ramsey-Goldman R, Reveille JD, Salmon JE, Tsao BP, Gibson KL, Byers JR, Vinnikova AK, Lea JP, Julian BA, Kimberly RP; Lupus Nephritis-End-Stage Renal Disease Consortium: End-stage renal disease in African Americans with lupus nephritis is associated with APOL1. Arthritis Rheumatol 66: 390-396, 2014
24. Bastian HM, Alarcón GS, Roseman JM, McGwin G Jr, Vilá LM, Fessler BJ, Reveille JD; LUMINA Study Group: Systemic lupus erythematosus in amultiethnicUS cohort (LUMINA) XL II: factors predictive of new or worsening proteinuria. Rheumatology (Oxford) 46: 683-689, 2007
25. McCarty GA, Harley JB, Reichlin M: A distinctive autoantibody profile in black female patients with lupus nephritis. Arthritis Rheum 36: 1560-1565, 1993
26. Alarcón GS: Multiethnic lupus cohorts: what have they taught us? Reumatol Clin 7: 3-6, 2011
27. Tektonidou M, Dasgupta A, Ward M: Risk of end-stage renal disease in patientswith lupus nephritis, 1970-2015: A systematic review and Bayesian meta-analysis. Arthritis Rheumatol 68: 1432-1441, 2016
28. Yap DYH, Tang CSO, Ma MKM, Lam MF, Chan TM: Survival analysis and causes of mortality in patients with lupus nephritis. Nephrol Dial Transplant 27: 3248-3254, 2012
29. Lerang K, Gilboe I-M, Steinar Thelle D, Gran JT: Mortality and years of potential life loss in systemic lupus erythematosus: a population-based cohort study. Lupus 23: 1546-1552, 2014
30. Bernatsky S, Boivin JF, Joseph L, Manzi S, Ginzler E, Gladman DD, Urowitz M, Fortin PR, Petri M, Barr S, Gordon C, Bae SC, Isenberg D, Zoma A, Aranow C, Dooley MA, Nived O, Sturfelt G, Steinsson K, Alarcón G, Senécal JL, Zummer M, Hanly J, Ensworth S, Pope J, Edworthy S, Rahman A, Sibley J, El-Gabalawy H, McCarthy T, St Pierre Y, Clarke A, Ramsey-Goldman R: Mortality in systemic lupus erythematosus. Arthritis Rheum 54: 2550-2557, 2006
31. Faurschou M, Dreyer L, Kamper AL, Starklint H, Jacobsen S: Long-term mortality and renal outcome in a cohort of 100 patientswith lupus nephritis. Arthritis Care Res (Hoboken) 62: 873-880, 2010
32. Chen YE, Korbet SM, Katz RS, Schwartz MM, Lewis EJ; Collaborative StudyGroup: Value of a complete or partial remission in severe lupus nephritis. Clin J Am Soc Nephrol 3: 46-53, 2008
33. Munroe ME, James JA: Genetics of Lupus Nephritis: Clinical Implications. Semin Nephrol 35: 396-409, 2015
34. Niu Z, Zhang P, Tong Y: Value of HLA-DR genotype in systemic lupus erythematosus and lupus nephritis: a meta-analysis. Int J Rheum Dis 18: 17-28, 2015
35. Miyadera H, Ohashi J, Lernmark Å, Kitamura T, Tokunaga K: Cellsurface MHC density profiling reveals instability of autoimmunityassociated HLA. J Clin Invest 125: 275-291, 2015
36. Miyadera H, Tokunaga K: Associations of human leukocyte antigens with autoimmune diseases: challenges in identifying the mechanism. J Hum Genet 60: 697-702, 2015
37. Chung SA, Brown EE, Williams AH, Ramos PS, Berthier CC, Bhangale T, Alarcon-Riquelme ME, Behrens TW, Criswell LA, Graham DC, Demirci FY, Edberg JC, Gaffney PM, Harley JB, Jacob CO, Kamboh MI, Kelly JA, Manzi S, Moser-Sivils KL, Russell LP, Petri M, Tsao BP, Vyse TJ, Zidovetzki R, Kretzler M, Kimberly RP, Freedman BI, Graham RR, Langefeld CD; International Consortium for Systemic Lupus Erythematosus Genetics: Lupus nephritis susceptibility loci in women with systemic lupus erythematosus. J Am Soc Nephrol 25: 2859-2870, 2014
38. Raffler J, Friedrich N, Arnold M, Kacprowski T, Rueedi R, Altmaier E, Bergmann S, Budde K, Gieger C, Homuth G, Pietzner M, Römisch-Margl W, Strauch K, Völzke H, Waldenberger M, Wallaschofski H, Nauck M, Vö lker U, Kastenmüller G, Suhre K: Genome-Wide Association Study with Targeted and Nontargeted NMR Metabolomics Identifies 15 Novel Loci of Urinary Human Metabolic Individuality. PLoS Genet 11: e1005487, 2015
39. Tsai LJ, Hsiao SH, Tsai LM, Lin CY, Tsai JJ, Liou DM, Lan JL: The sodium-dependent glucose cotransporter SLC5A11 as an autoimmune modifier gene in SLE. Tissue Antigens 71: 114-126, 2008
40. Banchereau R, Hong S, Cantarel B, Baldwin N, Baisch J, Edens M, Cepika AM, Acs P, Turner J, Anguiano E, Vinod P, Kahn S, Obermoser G, Blankenship D, Wakeland E, Nassi L, Gotte A, Punaro M, Liu YJ, Banchereau J, Rossello-Urgell J, Wright T, Pascual V: Personalized Immunomonitoring UncoversMolecular Networks that Stratify Lupus Patients. Cell 165: 551-565, 2016
41. Villanueva E, Yalavarthi S, Berthier CC, Hodgin JB, Khandpur R, Lin AM, Rubin CJ, Zhao W, Olsen SH, Klinker M, Shealy D, Denny MF, Plumas J, Chaperot L, Kretzler M, Bruce AT, Kaplan MJ: Netting neutrophils induce endothelial damage, infiltrate tissues, and expose immunostimulatory molecules in systemic lupus erythematosus. J Immunol 187: 538-552, 2011
42. Hakkim A, Fürnrohr BG, Amann K, Laube B, Abed UA, Brinkmann V, Herrmann M, Voll RE, Zychlinsky A: Impairment of neutrophil extracellular trap degradation is associated with lupus nephritis. Proc Natl Acad Sci U S A 107: 9813-9818, 2010
43. Birmingham DJ, Bitter JE, Ndukwe EG, Dials S, Gullo TR, Conroy S, Nagaraja HN, Rovin BH, Hebert LA: Relationship of Circulating Anti-C3b and Anti-C1q IgG to Lupus Nephritis and Its Flare. Clin J Am Soc Nephrol 11: 47-53, 2015
44. Pang Y, Yang XW, Song Y, Yu F, Zhao MH: Anti-C1q autoantibodies from active lupus nephritis patients could inhibit the clearance of apoptotic cells and complement classical pathway activation mediated by C1q in vitro. Immunobiology 219: 980-989, 2014
45. Gargiulo ML, Gómez G, Khoury M, Collado MV, Suárez L, Á lvarez C, Sarano J: Association between the presence of anti-C1q antibodies and active nephritis in patients with systemic lupus erythematosus. Medicina (B Aires) 75: 23-28, 2015
46. McKinney EF, Lee JC, Jayne DR, Lyons PA, Smith KG: T-cell exhaustion, co-stimulation and clinical outcome in autoimmunity and infection. Nature 523: 612-616, 2015
47. Christopher-Stine L, Siedner M, Lin J, Haas M, Parekh H, Petri M, Fine DM: Renal biopsy in lupus patients with low levels of proteinuria. J Rheumatol 34: 332-335, 2007
48. Fiehn C, Hajjar Y, Mueller K, Waldherr R, Ho AD, Andrassy K: Improved clinical outcome of lupus nephritis during the past decade: importance of early diagnosis and treatment. Ann Rheum Dis 62: 435-439, 2003
49. Rovin BH: Glomerular disease: Lupus nephritis treatment: are we beyond cyclophosphamide? Nat Rev Nephrol 5: 492-494, 2009
50. Song D, Wu LH, Wang FM, Yang XW, Zhu D, Chen M, Yu F, Liu G, Zhao MH: The spectrum of renal thrombotic microangiopathy in lupus nephritis. Arthritis Res Ther 15: R12, 2013
51. Hu W, Chen Y, Wang S, Chen H, Liu Z, Zeng C, Zhang H, Liu Z: Clinical-Morphological Features and Outcomes of Lupus Podocytopathy. Clin J Am Soc Nephrol 11: 585-592, 2016
52. Singh AK, Ucci A, Madias NE: Predominant tubulointerstitial lupus nephritis. Am J Kidney Dis 27: 273-278, 1996
53. Weening JJ, D’Agati VD, Schwartz MM, Seshan SV, Alpers CE, Appel GB, Balow JE, Bruijn JA, Cook T, Ferrario F, Fogo AB, Ginzler EM, Hebert L, Hill G, Hill P, Jennette JC, Kong NC, Lesavre P, Lockshin M, Looi L-M, Makino H, Moura LA, Nagata M: The classification of glomerulonephritis in systemic lupus erythematosus revisited. J Am Soc Nephrol 15: 241-250, 2004
54. Peterson KS, Huang JF, Zhu J, D’Agati V, Liu X, Miller N, Erlander MG, Jackson MR, Winchester RJ: Characterization of heterogeneity in the molecular pathogenesis of lupus nephritis from transcriptional profiles of laser-captured glomeruli. J Clin Invest 113: 1722-1733, 2004
55. Bethunaickan R, Berthier CC, Zhang W, Kretzler M, Davidson A: Comparative transcriptional profiling of 3 murine models of SLE nephritis reveals both unique and shared regulatory networks. PLoS One 8: e77489, 2013
56. Parikh SV, Malvar A, Song H, Alberton V, Lococo B, Vance J, Zhang J, Yu L, Rovin BH: Characterising the immune profile of the kidney biopsy at lupus nephritis flare differentiates early treatment responders from non-responders. Lupus Sci Med 2: e000112, 2015
57. Malvar A, Pirruccio P, Alberton V, Lococo B, Recalde C, Fazini B, Nagaraja H, Indrakanti D, Rovin BH: Histologic versus clinical remission in proliferative lupus nephritis [published online ahead of print August 6, 2015]. Nephrol Dial Transplant doi:10.1093/ndt/gfv296, 2015
58. Zickert A, Sundelin B, Svenungsson E, Gunnarsson I: Role of early repeated renal biopsies in lupus nephritis. Lupus Sci Med 1: e000018, 2014
59. Alvarado AS, Malvar A, Lococo B, Alberton V, Toniolo F, Nagaraja HN, Rovin BH: The value of repeat kidney biopsy in quiescent Argentinian lupus nephritis patients. Lupus 23: 840-847, 2014
60. Kidney Disease Improving Global Outcomes (KDIGO) Glomerulonephritis Work Group: Kidney Int Suppl 2: 139-274, 2012
61. Parikh SV, Alvarado A, Malvar A, Rovin BH: The Kidney Biopsy in Lupus Nephritis: Past, Present, and Future. Semin Nephrol 35: 465-477, 2015
62. Hill GS, Delahousse M, Nochy D, Rémy P, Mignon F, Méry JP, Bariéty J: Predictive power of the second renal biopsy in lupus nephritis: significance of macrophages. Kidney Int 59: 304-316, 2001
63. Hill GS, Delahousse M, Nochy D, Tomkiewicz E, Rémy P, Mignon F, Méry JP: A new morphologic index for the evaluation of renal biopsies in lupus nephritis. Kidney Int 58: 1160-1173, 2000
64. Austin HA 3rd, Muenz LR, Joyce KM, Antonovych TA, Kullick ME, Klippel JH, Decker JL, Balow JE: Prognostic factors in lupus nephritis. Contribution of renal histologic data. Am J Med 75: 382-391, 1983
65. Alsuwaida A, Husain S, Alghonaim M, AlOudah N, Alwakeel J, ullah A, Kfoury H: Strategy for second kidney biopsy in patients with lupus nephritis. Nephrol Dial Transplant 27: 1472-1478, 2012
66. Bajaj S, Albert L, Gladman DD, Urowitz MB, Hallett DC, Ritchie S: Serial renal biopsy in systemic lupus erythematosus. J Rheumatol 27: 2822-2826, 2000
67. Daleboudt GM, Bajema IM, Goemaere NN, van Laar JM, Bruijn JA, Berger SP: The clinical relevance of a repeat biopsy in lupus nephritis flares. Nephrol Dial Transplant 24: 3712-3717, 2009
68. Greloni G, Scolnik M, Marin J, Lancioni E, Quiroz C, Zacariaz J, DelaIglesia Niveyro P, Christiansen S, Pierangelo MA, Varela CF, Rosa-Diez GJ, Catoggio LJ, Soriano ER: Value of repeat biopsy in lupus nephritis flares. Lupus Sci Med 1: e000004, 2014
69. Moroni G, Pasquali S, Quaglini S, Banfi G, Casanova S, Maccario M, Zucchelli P, Ponticelli C: Clinical and prognostic value of serial renal biopsies in lupus nephritis. AmJ Kidney Dis 34: 530-539, 1999
70. Pagni F, Galimberti S, Goffredo P, Basciu M, Malachina S, Pilla D, Galbiati E, Ferrario F: The value of repeat biopsy in the management of lupus nephritis: an international multicentre study in a large cohort of patients. Nephrol Dial Transplant 28: 3014-3023, 2013
71. Ginzler EM, Bollet AJ, Friedman EA: The natural history and response to therapy of lupus nephritis. Annu Rev Med 31: 463-487, 1980
72. Costenbader KH, Desai A, Alarcón GS, Hiraki LT, Shaykevich T, Brookhart MA, Massarotti E, Lu B, Solomon DH, Winkelmayer WC: Trends in the incidence, demographics, and outcomes of end-stage renal disease due to lupus nephritis in the US from 1995 to 2006. Arthritis Rheum 63: 1681-1688, 2011
73. Appel GB, Contreras G, Dooley MA, Ginzler EM, Isenberg D, Jayne D, Li L-S, Mysler E, Sánchez-Guerrero J, Solomons N, Wofsy D; Aspreva Lupus Management Study Group: Mycophenolate mofetil versus cyclophosphamide for induction treatment of lupus nephritis. J Am Soc Nephrol 20: 1103-1112, 2009
74. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, Garrido Ed ER, Danieli MG, Abramovicz D, Blockmans D, Mathieu A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns JP, Cervera R: Immunosuppressive therapy in lupus nephritis: the Euro-LupusNephritis Trial, a randomized trial of low-dose versus high-dose intravenous cyclophosphamide. Arthritis Rheum 46: 2121-2131, 2002
75. Rovin BH, Furie R, Latinis K, Looney RJ, Fervenza FC, Sanchez-Guerrero J, Maciuca R, Zhang D, Garg JP, Brunetta P, Appel G; LUNAR Investigator Group: Efficacy and safety of rituximab in patients with active proliferative lupus nephritis: the Lupus Nephritis Assessment with Rituximab study. Arthritis Rheum 64: 1215-1226, 2012
76. Parikh SV, Nagaraja HN, Hebert L, Rovin BH: Renal flare as a predictor of incident and progressive CKD in patients with lupus nephritis. Clin J Am Soc Nephrol 9: 279-284, 2014
77. Dooley MA, Jayne D, Ginzler EM, Isenberg D, Olsen NJ, Wofsy D, Eitner F, Appel GB, Contreras G, Lisk L, Solomons N; ALMS Group: Mycophenolate versus azathioprine as maintenance therapy for lupus nephritis. N Engl JMed 365: 1886-1895, 2011
78. Houssiau FA, Vasconcelos C, D’Cruz D, Sebastiani GD, de Ramon Garrido E, Danieli MG, Abramovicz D, Blockmans D, Cauli A, Direskeneli H, Galeazzi M, Gül A, Levy Y, Petera P, Popovic R, Petrovic R, Sinico RA, Cattaneo R, Font J, Depresseux G, Cosyns J-P, Cervera R: The 10-year follow-up data of the Euro-Lupus Nephritis Trial comparing low-dose and high-dose intravenous cyclophosphamide. Ann Rheum Dis 69: 61-64, 2010
79. Parikh SV, Rovin BH: Current and Emerging Therapies for Lupus Nephritis [published online ahead of print June 9, 2016]. J Am Soc Nephrol doi:10.1681/ASN.2016040415, 2016
80. Dall’Era M, Levesque V, Solomons N, Truman M, Wofsy D: Identification of clinical and serological factors during induction treatment of lupus nephritis that are associated with renal outcome. Lupus Sci Med 2: e000089, 2015
81. Austin HAI 3rd, Klippel JH, Balow JE, le Riche NGH, Steinberg AD, Plotz PH, Decker JL: Therapy of lupus nephritis. Controlled trial of prednisone and cytotoxic drugs. N Engl JMed 314: 614-619, 1986
82. ACCESS Trial Group: Treatment of lupus nephritis with abatacept: the Abatacept and Cyclophosphamide Combination Efficacy and Safety Study. Arthritis Rheumatol 66: 3096-3104, 2014
83. Galbraith L, Manns B, Hemmelgarn B, Walsh M: The Steroids In the Maintenance of remission of Proliferative Lupus nephritis (SIMPL) pilot trial. Can J Kidney Health Dis 1: 30, 2014
84. Naik A, Sharma S, Quigg RJ: Complement regulation in renal disease models. Semin Nephrol 33: 575-585, 2013
85. Xiao H, Dairaghi DJ, Powers JP, Ertl LS, Baumgart T, Wang Y, Seitz LC, Penfold ME, Gan L, Hu P, Lu B, Gerard NP, Gerard C, Schall TJ, Jaen JC, Falk RJ, Jennette JC: C5a receptor (CD88) blockade protects against MPO-ANCA GN. J Am Soc Nephrol 25: 225-231, 2014
86. Enia G, Catalano C, Misefari V, Salnitro F, Mundo N, Tetta C, Maggiore Q: Complement activated leucopenia during hemodialysis: effect of pulse methyl-prednisolone. Int J Artif Organs 13: 98-102, 1990
87. Vollmer TL, Sorensen PS, Selmaj K, Zipp F, Havrdova E, Cohen JA, Sasson N, Gilgun-Sherki Y, Arnold DL; BRAVO Study Group: A randomized placebo-controlled phase III trial of oral laquinimod for multiple sclerosis. J Neurol 261: 773-783, 2014
88. Lourenço EV, Wong M, Hahn BH, Palma-Diaz MF, Skaggs BJ: Laquinimod delays and suppresses nephritis in lupus-prone mice and affects both myeloid and lymphoid immune cells. Arthritis Rheumatol 66: 674-685, 2014
89. Jayne D, Appel G, Chan TM, Mimrod D, Spiegelstein O, Barkay H, Weiss R, Wofsy D: The pharmacokinetics of laquinimod and mycophenolate mofetil during treatment of active lupus nephritis. Presented at the 2013 American Society of Nephrology Annual Meeting, Atlanta, GA, November 5-10, 2013
90. Weng J, Lai P, Lv M, Lin S, Ling W, Geng S, Luo C, Liu X, Du X: Bortezomib modulates regulatory T cell subpopulations in the process of acute graft-versus-host disease. Clin Lab 59: 51-58, 2013
91. Dooley MA, Houssiau F, Aranow C, D’Cruz DP, Askanase A, Roth DA, Zhong ZJ, Cooper S, Freimuth WW, Ginzler EM; BLISS-52 and-76 Study Groups: Effect of belimumab treatment on renal outcomes: results from the phase 3 belimumab clinical trials in patients with SLE. Lupus 22: 63-72, 2013
92. Rovin BH, Dooley MA, Radhakrishnan J, Ginzler EM, Forrester TD, Anderson PW: The impact of tabalumab on the kidney in systemic lupus erythematosus: results from two phase 3 randomized, clinical trials [published online ahead of print, may 24, 2016]. Lupus doi:10.1177/0961203316650734, 2016
93. Gallagher KM, Lauder S, Rees IW, Gallimore AM, Godkin AJ: Type I interferon (IFN alpha) acts directly on human memory CD41 T cells altering their response to antigen. J Immunol 183: 2915-2920, 2009
94. Jego G, Palucka AK, Blanck JP, Chalouni C, Pascual V, Banchereau J: Plasmacytoid dendritic cells induce plasma cell differentiation through type I interferon and interleukin 6. Immunity 19: 225-234, 2003
95. Rönnblom L, Alm GV, Eloranta ML: The type I interferon system in the development of lupus. Semin Immunol 23: 113-121, 2011
96. Tsuda K, Yamanaka K, Kitagawa H, Akeda T, Naka M, Niwa K, Nakanishi T, Kakeda M, Gabazza EC, Mizutani H: Calcineurin inhibitors suppress cytokine production frommemory T cells and differentiation of naïve T cells into cytokine-producing mature T cells. PLoS One 7: e31465, 2012
97. Liu Z, Zhang H, Liu Z, Xing C, Fu P, Ni Z, Chen J, Lin H, Liu F, He Y, He Y, Miao L, Chen N, Li Y, Gu Y, Shi W, Hu W, Liu Z, Bao H, Zeng C, Zhou M: Multitarget Therapy for Induction Treatment of Lupus Nephritis: A Randomized Trial. Ann Intern Med 162: 18-26, 2015
98. Mok CC, Ying KY, Yim CW, Siu YP, Tong KH, To CH, Ng WL: Tacrolimus versus mycophenolate mofetil for induction therapy of lupus nephritis: a randomised controlled trial and long-term follow-up. Ann Rheum Dis 75: 30-36, 2016
99. Jakes RW, Bae S-C, Louthrenoo W, Mok C-C, Navarra SV, Kwon N: Systematic review of the epidemiology of systemic lupus erythematosus in the Asia-Pacific region: prevalence, incidence, clinical features, and mortality. Arthritis Care Res (Hoboken) 64: 159-168, 2012